Charles River Laboratories International, Inc. Share Price Deutsche Boerse AG

Equities

RV6

US1598641074

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG 07:25:20 26/04/2024 BST 5-day change 1st Jan Change
212.6 EUR -4.10% Intraday chart for Charles River Laboratories International, Inc. -0.79% -0.70%

Financials

Sales 2024 * 4.22B 3.95B 338B Sales 2025 * 4.54B 4.25B 364B Capitalization 11.76B 11B 941B
Net income 2024 * 420M 393M 33.62B Net income 2025 * 525M 491M 42.03B EV / Sales 2024 * 3.25 x
Net Debt 2024 * 1.98B 1.86B 159B Net Debt 2025 * 1.51B 1.42B 121B EV / Sales 2025 * 2.92 x
P/E ratio 2024 *
28.3 x
P/E ratio 2025 *
23 x
Employees 21,100
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.19%
More Fundamentals * Assessed data
Dynamic Chart
FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids CI
Charles River Laboratories Files Supplement to Definitive Proxy Statement with the Securities and Exchange Commission CI
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing CI
Zacks Investment Research Adjusts Charles River Laboratories International's Price Target to $259 From $278 MT
Charles River Laboratories International, Inc. and Deciphex Limited Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology CI
Charles River Laboratories, Axovia Therapeutics Collaborate on Developing Rare Disease Gene Therapies MT
Charles River Laboratories International, Inc. Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics CI
Charles River Laboratories Signs Plasmid DNA Manufacturing Deal With Ship of Theseus MT
Charles River Laboratories International, Inc. and Ship of Theseus Announces Good Manufacturing Practice Plasmid DNA Contract Development and Manufacturing Organization Agreement CI
Charles River Laboratories International, Inc Receives a Shareholder Proposal from People for the Ethical Treatment of Animals CI
Deutsche Bank Raises Price Target on Charles River Laboratories to $300 From $275, Keeps Buy Rating MT
Charles River Laboratories International, Inc. Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine CI
Argus Raises Price Target on Charles River Laboratories International to $290 From $200, Maintains Buy Rating MT
Charles River Laboratories International, Navega Therapeutics Partner for Production of AAV-Based Gene Therapy MT
Charles River Laboratories International, Inc. and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration CI
More news
1 day-4.10%
1 week-0.79%
Current month-14.31%
1 month-12.98%
3 months+8.19%
6 months+30.63%
Current year-0.70%
More quotes
1 week
212.40
Extreme 212.4
224.10
1 month
212.40
Extreme 212.4
249.60
Current year
186.05
Extreme 186.05
251.80
1 year
154.45
Extreme 154.45
251.80
3 years
154.45
Extreme 154.45
388.00
5 years
88.50
Extreme 88.5
388.00
10 years
36.02
Extreme 36.023
388.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 73 31/12/75
Director of Finance/CFO 51 24/04/22
Chief Operating Officer 54 31/03/89
Members of the board TitleAgeSince
Director/Board Member 78 02/12/07
Director/Board Member 76 31/12/02
Director/Board Member 68 30/09/19
More insiders
Date Price Change
26/04/24 212.6 -4.10%
25/04/24 221.7 -1.07%
24/04/24 224.1 +2.99%
23/04/24 217.6 +2.45%
22/04/24 212.4 -0.89%

Delayed Quote Deutsche Boerse AG, April 26, 2024 at 07:25 am

More quotes
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (63.4%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (19.2%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (17.5%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (83.3%) and sales of products (16.7%). Net sales are distributed geographically as follows: the United States (56.8%), Europe (26%), Canada (11.8%), Asia/Pacific (4.9%) and other (0.4%).
Calendar
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
229 USD
Average target price
270.7 USD
Spread / Average Target
+18.18%
Consensus